InSights Videos
Special Edition: A Combined Fundraising & Partnering Strategy – a Better Way to Secure Success?
In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of PharmaVentures, leads a panel discussion to address whether a dual fundraising and partnering strategy is the best way forward for an emerging biotech. Panelists...
Contract Manufacturing in the Pharmaceutical Industry: Recipharm
In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm. Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in...
PharmaVentures InSights: The impact of conference cancellations on dealmaking during the Covid-19 pandemic
Can Partnering Conference Cancellations Affect Dealmaking in 2020? We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we...
The Divestment Challenge Interview
In this special edition of PharmaVentures Insights, we explore the challenges faced by pharmaceutical companies during the manufacturing divestment process, and how to accelerate the divestment process to achieve a successful outcome. Paul Larsmon spoke with leading...
Doing deals in the healthcare sector during the Covid-19 pandemic.
The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals. https://youtu.be/o81Th7McuHA
Key Questions When Doing a Deal with Big Pharma: A Conversation with PharmaVentures (한국어 버전)
What are the most important things to think about when doing a licensing deal with Western big pharma? How do you engage with them and keep the momentum going? Can language become a barrier in doing a deal? How is the Korean biopharmaceutical sector viewed by those of...
Why you should make South Korea a deal making target
Over the past couple of years, we have seen huge growth in the pharma and biotech industries in Asia, and especially in Korea. Historically, the Korean pharmaceutical industry was built on manufacturing and generics capabilities, however, in the past few decades many...
Video Interview: NetScientific, Fighting chronic diseases on three fronts.
With more than 89 million chronic disease sufferers in the US alone, NetScienctific is focused on fighting chronic diseases on three fronts to create 'next generation healthcare technologies'. Thier healthcare investment strategy is building businesses in digital...
Featured Videos
Manufacturing Operations Divestment Expertise
Visit our YouTube channel for more videos
Blog Articles
Vaccines, patents and supply
by Dr Fintan Walton, CEO, PharmaVentures. In my experience, quick fix solutions to complex issues...
PharmaVentures’ Industry Insight: We predict that licensing and partnering activity will remain steady in 2020
As we all know deal making is the life and blood of the biopharma industry and today this activity...
Are you Planning to Divest R&D or Manufacturing Facilities?
To download the full article please click here
PharmaVentures are Media Partners at the World Stem Cells & Regenerative Medicine Congress 2015
PharmaVentures and PharmaTelevision are delighted to be Media Partners at the World Stem...
Season’s Greetings from PharmaVentures 2014
Convergence of Healthcare with ICT accelerates
By Ping ShekThe healthcare market today is driven by the overriding need to deliver better patient...
Pfizer/AZ: The bigger issue is not M&A but how in the future we find effective medicines
The debate and discussions in the media on the attempted bid by Pfizer for AstraZeneca (AZ)...
Pfizer+AZ: Will Mega-Merger Mania Return?
Today the talking point, of course, is the bid by Pfizer for AstraZeneca (AZ) and whether...
Pharma is attracted to early-stage antibody deals in Oncology
Today, the top ten best-selling antibody therapeutics for cancer have accumulated revenues...
Can 2014 be better than 2013?
I predict that 2014 will be a year where the pharmaceutical industry will be stronger,...
Season’s Greetings from PharmaVentures
Biotech Bounces Back
On the 31st July of this year the Financial Times front page headline to its Companies and Markets...
White Papers
Non-Small Cell Lung Cancer (NSCLC)
NSCLC is one of the most active areas of innovation in Oncology, and recent consensus estimates indicate that an additional $20BN of sales could be added in the indication over the next few years.
Our News
PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH
Oxford, UK, 03 March 2021 PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH. ERA Consulting is a leading strategic product development and regulatory consulting group serving the...